Akkermansia muciniphila HHAKKα Prevents High-Fat Diet-Induced Obesity in Mice via Gut Microbiota Modulation and Regulation of Hepatic Lipid Metabolism.

Summary

This experimental study demonstrates that oral administration of a specific Akkermansia muciniphila strain (HHAKKα) significantly reduces weight gain in high-fat diet-fed mice to a degree comparable with orlistat, through multiple interconnected mechanisms. The intervention modulates gut microbiota composition (increasing beneficial taxa, reducing the Bacillota/Bacteroidota ratio by 55.35%), substantially increases fecal short-chain fatty acids (butyrate restored to ~1.5× baseline), suppresses systemic inflammation, improves lipid and glucose profiles, and regulates hepatic lipid synthesis gene expression. The findings suggest potential therapeutic applications for obesity management via microbiota-targeted intervention.

Regional applicability

This is a murine laboratory study and does not directly translate to human clinical settings or United Kingdom agricultural/dietary practice. However, the mechanistic insights regarding A. muciniphila, short-chain fatty acid production, and lipid metabolism may inform future human clinical trials and dietary or probiotic interventions relevant to UK obesity and metabolic disease management.

Key measures

Body weight gain (g), glucose homeostasis, serum triglycerides, LDL-cholesterol, adiponectin, GLP-1, pro-inflammatory cytokines (TNF-α, IL-1β, MCP-1), Bacillota/Bacteroidota ratio (%), fecal butyrate concentration, FASN and PGC-1α expression

Outcomes reported

The study measured weight gain, glucose homeostasis, serum lipid profiles, inflammatory cytokines, hepatic steatosis, gut microbiota composition, fecal short-chain fatty acids, and hepatic gene expression (FASN, PGC-1α) in high-fat diet-induced obese mice treated with A. muciniphila HHAKKα.

Topic tags